Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367661 | 0.93 | RET (0.36) | RETSMYD3HRH4HRH3GABRA2 | |
| SCHEMBL12203587 | 0.86 | HRH4 (0.37) | RETHRH4GABRA2GABRB2 | |
| SCHEMBL18161139 | 0.86 | PSMB8 (0.35) | RETSMYD3HRH4HRH3GABRA2 | |
| SCHEMBL19625281 | 0.84 | HRH4 (0.39) | RETHRH4GABRA2GABRB2 | |
| SCHEMBL18367634 | 0.83 | DRD2 (0.33) | RETSMYD3GABRA2GABRB2MEN1 | |
| SCHEMBL19589565 | 0.81 | CHRNB2 (0.36) | RETHRH4HRH3GABRA2GABRB2 | |
| SCHEMBL18367573 | 0.81 | CNR2 (0.38) | RETGABRA2GABRB2 | |
| SCHEMBL18367582 | 0.80 | DRD2 (0.33) | RETGABRA2GABRB2 | |
| SCHEMBL18367629 | 0.78 | GSK3B (0.36) | RETHRH3MEN1KMT2A | |
| SCHEMBL18367602 | 0.78 | DRD4 (0.40) | HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | RET 3585/4885SMYD3 2820/4885HRH4 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.